# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Michael Ulz reiterates Viking Therapeutics (NASDAQ:VKTX) with a Overweight and maintains $105 price t...
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price ta...
JP Morgan analyst Hardik Parikh initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and announc...
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...
- Reuters
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.